Johnson & JohnsonvsUroGen Pharma

JNJ and URGN stock compared: price, dividend, valuation and results, from SEC filings.

Johnson & Johnson (JNJ) has a market value of $652B and UroGen Pharma (URGN) $1.3B. Over the last year, with dividends, JNJ moved +36.6% and URGN +9.4%. Dividend yield: JNJ 1.95%, URGN none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$652B

    URGN$1.3B

    JNJ is 484 times URGN

  • Revenue, 12 months

    JNJ$99.3B

    URGN$250M

    JNJ is 397 times URGN

  • Net income, 12 months

    JNJ$16.1B

    URGN-$66M

  • Operating margin

    JNJ–

    URGN-12.4%

  • ROIC

    JNJ12.4%

    URGN-58.4%

    70.8 points apart

  • P/E

    JNJ40.5

    URGN–

  • Dividend yield

    JNJ2.0%

    URGN0.0%

    2.0 points apart

  • 5-year return

    JNJ+90.9%

    URGN+129.3%

    38.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+90.9%

URGN+129.3%

20040020222023202420252026
Returns by period
PeriodJNJWith dividendsURGNWith dividends
1 year since November 19, 2025+36.6%Price +33.6%+9.4%Price +9.4%
3 years since November 20, 2023+94.9%+24.9% a yearPrice +80.4%+122.4%+30.5% a yearPrice +122.4%
5 years since November 19, 2021+90.9%+13.8% a yearPrice +66.0%+129.3%+18.1% a yearPrice +129.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonURGNUroGen Pharma

Valuation

JNJURGN
Valuation
Price$270.47$27.65
Market value$652B$1.3B
Enterprise value (EV)$679B$1.4B
P/E40.5–
P/E, 5-year median21.9–
P/B8.0–
EV/EBIT38.3–
Free cash flow yield3.2%–

Results and growth

JNJURGN
Results and growth
Revenue, 12 months$99.3B$250M
Net income, 12 months$16.1B-$66M
Free cash flow, 12 months$20.6B-$132M
Earnings per share, 12 months$6.59-$1.31
Revenue growth, year on year6.1%21.5%
Revenue growth a year, past+2.7%over 5 years+56.2%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJURGN
Margins and returns on capital
Gross margin67.6%91.4%
Operating margin–-12.4%
Net margin16.2%-26.3%
ROIC12.4%-58.4%
ROE19.7%–

Balance sheet

JNJURGN
Balance sheet
Cash$17.2B$91M
Total debt$44.7B$196M
Net debt / EBITDA1.1–
Interest cover18.0×–

Dividends and buybacks

JNJURGN
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or URGN

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or UroGen Pharma?

By market value, Johnson & Johnson ($652B) is about 484.2 times UroGen Pharma ($1.3B), at today's prices.

How did JNJ and URGN stock do over the last 5 years?

Since November 19, 2021, JNJ's price moved +66.0% and URGN's +129.3%. With dividends: JNJ +90.9% (+13.8% a year), URGN +129.3% (+18.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or URGN?

The dividend yield at today's price is 1.95% for Johnson & Johnson and none for UroGen Pharma. Over the last twelve months they paid $5.28 and – per share.

Which has the higher profit margins, Johnson & Johnson or UroGen Pharma?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and -26.3% for UroGen Pharma, and the operating margin – and -12.4%. Revenue was $99.3B and $250M.

Which is the better investment, Johnson & Johnson or UroGen Pharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.